Copyright
©The Author(s) 2017.
World J Virol. May 12, 2017; 6(2): 36-45
Published online May 12, 2017. doi: 10.5501/wjv.v6.i2.36
Published online May 12, 2017. doi: 10.5501/wjv.v6.i2.36
Table 1 Demographic, clinical and laboratory characteristics of the patients, according to the existence or not of significant liver fibrosis (≥ F2)
| All patients (n = 158) | No fibrosis (n = 124) | Fibrosis (n = 34) | P value | |
| Demography, epidemiology, anthropometry and habits | ||||
| Age (yr) | 44.56 (43.20-45.92) | 44.50 (42.93-46.07) | 44.79 (41.96-47.63) | 0.9 |
| Male, n (%) | 104 (65.8) | 78 (62.9) | 26 (76.5) | 0.14 |
| Weight (kg) | 65.17 (62.88-67.46) | 64.46 (61.72-67.20) | 67.76 (64.03-71.50) | 0.24 |
| Height (cm) | 164.4 (160.6-168.2) | 163.4 (158.5-168.2) | 168.2 (166.2-170.2) | 0.3 |
| Body mass index (kg/m2) | 23.58 (23.10-24.05) | 23.48 (22.95-24.01) | 23.90 (22.75-25.0.6) | 0.5 |
| Tobacco smokers, n (%) | 105 (66.5) | 78 (62.9) | 27 (79.4) | 0.07 |
| Cannabis use, n (%) | 38 (24.1) | 22 (17.7) | 16 (47.1) | 0.0004 |
| Alcohol intake, n (%)1 | 55 (35.0) | 43 (34.7) | 12 (36.4) | 0.9 |
| IDU, n (%) | 58 (36.9) | 29 (23.6) | 29 (85.6) | < 0.0001 |
| Men who have sex with men, n (%) | 28 (17.8) | 27 (22.0) | 1 (2.9) | 0.01 |
| Heterosexual, n (%) | 67 (42.7) | 63 (51.2) | 4 (11.8) | < 0.0001 |
| Transfusion, n (%) | 4 (2.5) | 4 (3.3) | 0 (0.0) | 0.3 |
| HIV-related parameters | ||||
| Current CD4 counts (cells/μL) | 581.5 (533.0-630.1) | 612.3 (555.8-668.8) | 469.6 (383.7-555.4) | 0.017 |
| Nadir CD4 counts (cells/μL) | 201.8 (176.5-227.1) | 213.4 (183.4-243.4) | 159.7 (116.7-202.6) | 0.04 |
| CD4 gain (cells/μL) | 379.7 (334.4-425.0) | 399.0 (345.4-452.6) | 309.9 (231.4-388.4) | 0.11 |
| Undetectable HIV viral load, n (%) | 135 (85.4) | 109 (87.9) | 26 (76.5) | 0.09 |
| HIV viral load (log copies/mL)2 | 2.996 (2.556-3.434) | 2.991 (2.407-3.575) | 3.006 (2.173-3.840) | 0.97 |
| Years of HIV infection | 11.93 (11.12-12.73) | 11.31 (10.39-12.22) | 14.19 (12.70-15.68) | 0.003 |
| Months on antiretroviral therapy | 114.3 (106.8-121.8) | 109.9 (101.3-118.5) | 130.2 (115.0-145.3) | 0.03 |
| CDC clinical stage, n (%) | ||||
| A | 84 (53.5) | 65 (52.8) | 19 (55.9) | 0.07 |
| B | 23 (14.6) | 22 (17.9) | 1 (2.9) | |
| C | 50 (31.8) | 36 (29.3) | 14 (41.2) | |
| HCV-related parameters | ||||
| HCV infection, n (%) | 57 (36.1) | 25 (20.2) | 32 (94.1) | < 0.0001 |
| HCV viral load (log copies/mL) | 5.745 (5.504-5.985) | 5.524 (5.085-5.964) | 5.915 (5.649-6.181) | 0.11 |
| Years of HCV infection | 22.46 (20.71-24.21) | 21.84 (18.96-24.72) | 22.94 (20.65-25.23) | 0.5 |
| HCV genotype, n (%) | ||||
| 1 | 31 (54.4) | 14 (56.0) | 17 (53.1) | 0.7 |
| 2 | 2 (1.3) | 1 (4.0) | 1 (3.1) | |
| 3 | 15 (23.6) | 5 (20.0) | 10 (31.3) | |
| 4 | 9 (15.8) | 5 (20.0) | 4 (12.5) | |
| Liver fibrosis parameters | ||||
| Transient elastometry (kPa) | 7.53 (5.99-9.06) | 4.65 (4.45-4.85) | 18.02 (11.93-24.10) | < 0.0001 |
| APRI | 0.633 (0.511-0.756) | 0.385 (0.346-0.423) | 1.541 (1.093-1.989) | < 0.0001 |
| Forns | 4.412 (4.116-4.707) | 3.990 (3.734-4.246) | 5.949 (5.095-6.802) | 0.0001 |
| FIB-4 | 1.475 (1.249-1.700) | 1.088 (0.985-1.191) | 2.884 (2.031-3.736) | 0.0002 |
| YFPI3 | 0.584 (0.416-0.752) | 0.281 (0.222-0.340) | 0.821 (0.548-1.095) | 0.0004 |
| Degree of liver fibrosis, n (%) | ||||
| F0-F1 | 124 (78.5) | 124 (100) | 0 (0.0) | < 0.0001 |
| F2 | 15 (9.5) | 0 (0.0) | 15 (44.1) | |
| F3 | 10 (6.3) | 0 (0.0) | 10 (29.4) | |
| F4 | 9 (5.7) | 0 (0.0) | 9 (26.5) | |
| Laboratory parameters | ||||
| Platelet count (/μL) | 222570 (211690-233450) | 236750 (225410-248090) | 169270 (147220-191330) | < 0.0001 |
| Glucose (mg/dL) | 98.54 (95.25-101.84) | 98.00 (94.62-101.38) | 100.66 (90.92-110.39) | 0.5 |
| Total cholesterol (mg/dL) | 195.01 (188.51-201.51) | 201.0 (193.8-208.3) | 173.0 (160.6-185.4) | 0.0004 |
| HDL cholesterol (mg/dL) | 49.33 (46.88-51.78) | 49.42 (46.95-52.29) | 48.25 (42.02-54.48) | 0.7 |
| LDL cholesterol (mg/dL) | 110.73 (104.68-116.77) | 116.97 (110.22-123.72) | 87.53 (76.91-98.16) | 0.0001 |
| Triglycerides (mg/dL) | 199.79 (170.08-229.50) | 189.0 (157.5-220.5) | 241.7 (161.4-322.0) | 0.22 |
| AST (UI/mL) | 40.89 (36.01-45.78) | 30.72 (28.30-33.13) | 78.00 (62.01-93.99) | < 0.0001 |
| ALT (UI/mL) | 47.82 (40.54-55.09) | 36.91 (32.03-41.79) | 87.59 (62.16-113.02) | 0.0003 |
| AST/ALT ratio | 1.011 (0.949-1.074) | 0.993 (0.927-1.059) | 1.079 (0.913-1.246) | 0.3 |
| GGT (UI/mL) | 83.95 (66.61-101.29) | 59.73 (48.40-71.07) | 174.21 (110.61-237.81) | 0.001 |
| Alkaline phosphatase (UI/mL) | 91.87 (85.09-98.65) | 90.72 (83.22-98.23) | 98.31 (81.46-115.17) | 0.4 |
| MMP-2 (ng/mL) | 0.538 (0.442-0.654) | 0.482 (0.387-0.600) | 0.867 (0.579-1.300) | 0.02 |
| MMP-3 (ng/mL) | 15.00 (13.24-17.01) | 14.36 (12.47-16.54) | 17.77 (14.45-23.49) | 0.18 |
| MMP-8 (ng/mL) | 0.031 (0.023-0.041) | 0.029 (0.021-0.039) | 0.040 (0.020-0.078) | 0.4 |
| MMP-9 (ng/mL) | 22.49 (18.81-26.90) | 23.19 (19.00-28.31) | 19.94 (13.01-30.58) | 0.5 |
| MMP-10 (ng/mL) | 2.50 (1.66-3.75) | 2.163 (1.487-3.145) | 5.077 (0.938-27.469) | 0.12 |
| TIMP-1 (ng/mL) | 50.56 (45.58-56.08) | 50.84 (45.43-56.88) | 49.49 (37.71-64.94) | 0.8 |
| TIMP-2 (ng/mL) | 8.23 (7.16-9.46) | 7.62 (6.59-8.80) | 11.15 (7.55-16.45) | 0.03 |
| TIMP-4 (ng/mL) | 0.040 (0.030-0.054) | 0.037 (0.027-0.051) | 0.054 (0.026-0.110) | 0. 3 |
- Citation: Collazos J, Valle-Garay E, Suárez-Zarracina T, Montes AH, Cartón JA, Asensi V. Matrix metalloproteases and their tissue inhibitors in non-alcoholic liver fibrosis of human immunodeficiency virus-infected patients. World J Virol 2017; 6(2): 36-45
- URL: https://www.wjgnet.com/2220-3249/full/v6/i2/36.htm
- DOI: https://dx.doi.org/10.5501/wjv.v6.i2.36